Hepatic Neoplasia

Latest Articles

Viral Exposure Signature Predicts Hepatocellular Carcinoma

A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients.

Immunotherapy Regimen Approved for Hepatocellular Carcinoma

By

Brian Park, PharmD

The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC

By

Leah Lawrence

The combination resulted in durable response in many patients.

HCC Risk Lower With Higher Intake of Vegetable Fats, Polyunsaturated Fats

By

Jessica Nye, PhD

The source of fats in an individual’s diet may alter the risk of developing hepatocellular carcinoma.

QoL Extended With Atezolizumab + Bevacizumab in Liver Cancer

For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.

Active Hepatocellular Carcinoma as a Risk Factor for DAA Treatment Failure

By

Gastroenterology Advisor Contributing Writer

Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.

Tumor Size, Stiffness May Be Relevant Biomarkers of Response to ICIs in HCC

By

Randi Hernandez

The median change in HCC tumor size between responders and nonresponders was statistically significant.

Atezolizumab + Bevacizumab Prolongs Maintenance of QoL vs Sorafenib in Certain Patients With HCC

By

Susan Moench, PhD, PA-C

In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.

Integrating Palliative Care Into Hepatocellular Carcinoma Treatment

By

Tori Rodriquez, MA, LPC, AHC

The review authors used existing evidence to recommend a new model of palliative care integration in patients with hepatocellular carcinoma.

Prior Exposure to Antibiotics, Antacids Did Not Reduce IO Response in HCC

By

Randi Hernandez

Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.

In Intrahepatic Cholangiocarcinoma, Genomic Profiles of Primary Tumors and Metastatic Lesions Differ

By

Susan Moench, PhD, PA-C

Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.

PHGDH as a Potential Target in HCC Following Sorafenib Resistance

By

Christina Bennett, MS

PHGDH may be a possible target for overcoming sorafenib resistance, preclinical evidence suggests.

Microbiome-Derived Therapy Gets Orphan Drug Status for Hepatocellular Carcinoma

By

Brian Park, PharmD

The Food and Drug Administration (FDA) has granted Orphan Drug designation to SFA001 (SFA Therapeutics) for the treatment of hepatocellular carcinoma (HCC).

Level of Hepatitis B Core-Related Antigen and Risk for Hepatocellular Carcinoma

By

Virginia A. Schad, PharmD, RPh

According to a recently published study, a high level of hepatitis B core-related antigen is a complementary risk factor for hepatocellular carcinoma development.

Leisure-Time Physical Activity Linked to Lower Cancer Risk

Leisure-time physical activity at recommended levels is associated with a significantly lower risk for seven cancer types.

Lipophilic Statins Decrease Hepatocellular Carcinoma and Death in Chronic Hepatitis

By

Virginia A. Schad, PharmD, RPh

From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.

First Duodenoscope With Disposable Elevator Piece Cleared by FDA

By

Dibash Kumar Das, PhD

The FDA has cleared the first duodenoscope with a disposable sterile elevator piece, a first in the United States. The design will reduce the number of parts that need to be cleaned and disinfected (reprocessed) between uses.

Investigational Farnesoid X Receptor Agonist Gets Fast Track Status for NASH

By

Brian Park, PharmD

The FDA has granted Fast Track designation to TERN-101 (Terns Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.

Natural History and Tumor Development: Adeno-Associated Virus in the Liver

By

Gastroenterology Advisor Contributing Writer

Study provides a portrait of wild-type AAV infection in the liver with an identification of molecular forms, viral genotypes, viral integrations, and helper virus relationship and with AAV insertions positive selected during HCC development on noncirrhotic liver, which challenges the concept of AAV as nonpathogenic.

When to Use Direct-Acting Antivirals in Hepatocellular Carcinoma

By

Christin Melton

Researchers found data that showed treatment with direct-acting antivirals in patients with hepatocellular carcinoma with advanced cirrhosis improves liver function and could be categorized as safe.